Preventing recurrent preterm birth with 125\u2009mg of 17‐alpha‐hydroxyprogesterone caproate

Abstract

There is strong evidence that weekly intramuscular (IM) injections of 250\u2009mg of 17‐alpha‐hydroxyprogesterone caproate (17‐OHPC) reduce the risk of recurrent preterm birth (PTB); however, whether a lower dose of 17‐OHPC could reduce the risk of recurrent PTB remains unclear. This study aimed to assess whether 125\u2009mg of 17‐OHPC reduces recurrent PTB among women with a prior singleton spontaneous PTB and cervical length >25\u2009mm.